
Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.
Vice President of Novavax.
Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.
At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.
Published: April 28th 2025 | Updated:
Published: April 28th 2025 | Updated: